Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
..think you'll find the target is 1,000 per month not per day...."The PSE vertical is led by Dr Steve Arrivo, who joined the Company in November 2023 as Senior Vice President of Business and Corporate Development. Through the remainder of 2024 and beyond, the Company's commercial team will have a focus on large accounts, particularly including concierge medicine cash-pay customers, as the quickest way both to increase sales volumes and positively impact cash flow (the test has a price of $950 and the team is seeking to increase orders to a level of 1,000 tests per month). In addition, the Company will seek national distribution partners to make the test more readily accessible across the whole of the US and utilise available capacity at the Company's CLIA-registered lab."
@pompal..the other scenario is they'll hit the sales target which is £12m of revenue p.a. from PSE alone and which covers the cash burn and assumes 0 sales from CIRT or any disposals...all to play for at these levels..
Reading some of these posts it does amaze me how few people realise that regardless of how amazing a new product could be it takes time for it to be adopted by medical communities. As Jon Burrows said, they're not selling widgets. PSE has only just been launched. If Steve Arrivo gets anywhere near his sales target of 2,500 tests per month then we'll have nothing to worry about and that's before we factor in that they're looking for partners to help scale which could come any day. It's interesting that so far there's been no significant institutional selling we're aware of via TR1's which tells me this the sensible bigger shareholders are sticking with it and are probably rubbing their hands with glee at the prospect of being able to top up on the back of this retail panic sell off
OBD are presenting at the Jefferies HC conference this week. Should generate some investor interest https://www.lse.co.uk/ShareChat.html?ShareTicker=OBD&share=Oxford-Biodyn#posting-rules
All round excellent news and would expect brokers to upgrade forecasts post July update...good to see DX back on top